AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report).

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Third Harmonic Bio, Inc. (THRD – Research Report). The ...

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

or small-molecule therapy (Roche/PTC's Evrysdi), and fewer patients initiated therapy (the first year of therapy is twice as expensive). We expect sales to stabilize at around $2 billion as the ...

SCIEX, a global leader in life science analytical technologies, announces the localization of the SCIEX Triple Quad 6500+ system and the QTRAP 6500+ system in China. This announcement marks another ...

Today, a brief rundown of news from PTC Therapeutics and Novartis, as well as updates from Amylyx Pharmaceuticals and Intercept Pharmaceuticals that you may have missed. Over the next three months, ...

As an array of developers push their Friedreich’s ataxia (FA) drugs along, PTC Therapeutics Inc.’s recent update on its program piqued thirst for the 15-lipoxygenase inhibitor vatiquinone. Warren, N.J ...

Nov 6 (Reuters) - Industrial software maker PTC (PTC.O), opens new tab forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...